S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Gold explodes past $2,000, here's what's next (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Gold explodes past $2,000, here's what's next (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Gold explodes past $2,000, here's what's next (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Gold explodes past $2,000, here's what's next (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Gold explodes past $2,000, here's what's next (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Gold explodes past $2,000, here's what's next (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Gold explodes past $2,000, here's what's next (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Gold explodes past $2,000, here's what's next (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture

Deciphera Pharmaceuticals (DCPH) Stock Forecast & Price Target

$16.06
+0.31 (+1.97%)
(As of 02/23/2024 ET)

Deciphera Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 6 Analyst Ratings

Analysts' Consensus Price Target

$22.60
40.72% Upside
High Forecast$30.00
Average Forecast$22.60
Low Forecast$14.00
TypeCurrent Forecast
2/24/23 to 2/24/24
1 Month Ago
1/25/23 to 1/25/24
3 Months Ago
11/26/22 to 11/26/23
1 Year Ago
2/24/22 to 2/24/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
7 Buy rating(s)
8 Buy rating(s)
6 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$22.60$24.57$22.56$22.22
Predicted Upside40.72% Upside72.24% Upside54.09% Upside33.49% Upside
Get Deciphera Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter.


DCPH Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DCPH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Deciphera Pharmaceuticals Stock vs. The Competition

TypeDeciphera PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.83
2.68
2.48
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside40.72% Upside1,898.92% Upside7.52% Upside
News Sentiment RatingVery Positive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/7/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$22.00 ➝ $23.00+64.05%
11/20/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral$14.00+15.13%
10/31/2023Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
10/31/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$25.00 ➝ $30.00+151.47%
10/30/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Overweight$18.00 ➝ $23.00+82.54%
3/15/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Outperform$23.00+37.31%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 07:10 PM ET.












DCPH Price Target - Frequently Asked Questions

What is Deciphera Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 6 analysts in the last year, the consensus rating for Deciphera Pharmaceuticals stock is Moderate Buy based on the current 1 hold rating and 5 buy ratings for DCPH. The average twelve-month price prediction for Deciphera Pharmaceuticals is $22.60 with a high price target of $30.00 and a low price target of $14.00. Learn more on DCPH's analyst rating history.

Do Wall Street analysts like Deciphera Pharmaceuticals more than its competitors?

Analysts like Deciphera Pharmaceuticals more than other Medical companies. The consensus rating score for Deciphera Pharmaceuticals is 2.83 while the average consensus rating score for medical companies is 2.68. Learn more on how DCPH compares to other companies.

Does Deciphera Pharmaceuticals's stock price have much upside?

According to analysts, Deciphera Pharmaceuticals's stock has a predicted upside of 67.51% based on their 12-month stock forecasts.

What analysts cover Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals has been rated by Stifel Nicolaus in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:DCPH) was last updated on 2/24/2024 by MarketBeat.com Staff